GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (OTCPK:TEVJF) » Definitions » Change In Other Working Capital

TEVJF (Teva Pharmaceutical Industries) Change In Other Working Capital : $0 Mil (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Teva Pharmaceutical Industries Change In Other Working Capital?

Teva Pharmaceutical Industries's Change In Other Working Capital for the quarter that ended in Sep. 2024 was $0 Mil. It means Teva Pharmaceutical Industries's Other Working Capital stayed the same from Jun. 2024 to Sep. 2024 .

Teva Pharmaceutical Industries's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $-1,525 Mil. It means Teva Pharmaceutical Industries's Other Working Capital declined by $1,525 Mil from Dec. 2022 to Dec. 2023 .

Teva Pharmaceutical Industries Change In Other Working Capital Historical Data

The historical data trend for Teva Pharmaceutical Industries's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Change In Other Working Capital Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,416.00 -1,473.00 -2,271.00 -828.00 -1,525.00

Teva Pharmaceutical Industries Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Teva Pharmaceutical Industries Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (OTCPK:TEVJF) » Definitions » Change In Other Working Capital
Comparable Companies
XTAE:KMDA XTAE:REKA XTAE:TKUN XTAE:NXTG XTAE:CNTC XTAE:PMCN-M ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB VTRS HKSE:03692 SZSE:000538 NBIX NSE:TORNTPHARM BOM:543904
Traded in Other Exchanges
TEVA:USA TEVA:Mexico TEVA:Israel 0LER:UK TEV:Germany TEV:Germany TEV:Germany T1EV34:Brazil TEV:Bulgaria TEVA:Austria
Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Website
https://www.tevapharm.com
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.